Applications of lentiviral vectors for biology and gene therapy of neurological disorders.
暂无分享,去创建一个
Philippe Hantraye | Tomas Björklund | Nicole Déglon | N. Déglon | Tomas Björklund | D. Kirik | P. Hantraye | C. Lundberg | J. Jakobsson | Johan Jakobsson | T. Carlsson | Thomas Carlsson | Deniz Kirik | Cecilia Lundberg | T. Björklund | Johan Jakobsson
[1] A. Björklund,et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. , 2005, Brain : a journal of neurology.
[2] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[3] A. Kingsman,et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.
[4] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[5] Lesion‐dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein‐lentiviral vector , 2004, The European journal of neuroscience.
[6] A. Björklund,et al. Generation of DOPA-Producing Astrocytes by Retroviral Transduction of the Human Tyrosine Hydroxylase Gene:In VitroCharacterization andin VivoEffects in the Rat Parkinson Model , 1996, Experimental Neurology.
[7] S. Wachtel,et al. Role of Aromatic l‐Amino Acid Decarboxylase for Dopamine Replacement by Genetically Modified Fibroblasts in a Rat Model of Parkinson's Disease , 1997, Journal of neurochemistry.
[8] Patrick Aebischer,et al. A versatile tool for conditional gene expression and knockdown , 2006 .
[9] A. Consiglio,et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice , 2001, Nature Medicine.
[10] Jochen Klucken,et al. Dopaminergic neuron loss and up‐regulation of chaperone protein mRNA induced by targeted over‐expression of alpha‐synuclein in mouse substantia nigra , 2007, Journal of neurochemistry.
[11] S. Leff,et al. Long-term restoration of striatal l-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease , 1999, Neuroscience.
[12] V. Hamburger,et al. In vitro experiments on the effects of mouse sarcomas 180 and 37 on the spinal and sympathetic ganglia of the chick embryo. , 1954, Cancer research.
[13] F. Gage,et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.
[14] A. Björklund,et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] N. Mazarakis,et al. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. , 2006, Clinical science.
[16] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[17] I. Martins,et al. In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins , 2002, Journal of Virology.
[18] H. Neumann. Microglia: a cellular vehicle for CNS gene therapy. , 2006, The Journal of clinical investigation.
[19] D. Kirik,et al. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. , 2004, Human gene therapy.
[20] S. Leff,et al. Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson’s Disease , 1998, The Journal of Neuroscience.
[21] Z. Tonar,et al. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain , 2007, Gene Therapy.
[22] A. Björklund,et al. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[23] L Naldini,et al. Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain , 2006, The journal of gene medicine.
[24] R. Levine,et al. GTP cyclohydrolase I induction in striatal astrocytes following intrastriatal kainic acid lesion , 2002, Journal of Chemical Neuroanatomy.
[25] R. Ridley,et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.
[26] S. Wiegand,et al. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Björklund,et al. Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.
[28] A. Björklund,et al. Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease , 1996, The Journal of Neuroscience.
[29] C. Henderson,et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS , 2005, Nature Medicine.
[30] C. Lundberg,et al. Evidence for disease‐regulated transgene expression in the brain with use of lentiviral vectors , 2006, Journal of neuroscience research.
[31] F. Gage,et al. Rescue from Photoreceptor Degeneration in therd Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer , 1999, Journal of Virology.
[32] Seppo Ylä-Herttuala,et al. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain , 2006, The journal of gene medicine.
[33] K. Lange,et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[34] Inder M Verma,et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[35] A. Björklund,et al. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector , 2002, Neuroreport.
[36] J. Paton,et al. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain , 2008, The journal of gene medicine.
[37] F. Cosset,et al. Strategies for targeting lentiviral vectors. , 2008, Current gene therapy.
[38] K. Lindenberg,et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. , 2002, Molecular cell.
[39] E. Hirsch,et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. , 2006, Molecular biology of the cell.
[40] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[41] B. Nuttin,et al. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. , 2003, Human gene therapy.
[42] B. Davidson,et al. Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.
[43] S. Leff,et al. In VivoL-DOPA Production by Genetically Modified Primary Rat Fibroblast or 9L Gliosarcoma Cell Grafts via Coexpression of GTPcyclohydrolase I with Tyrosine Hydroxylase , 1998, Experimental Neurology.
[44] N. Déglon,et al. Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease , 2001, Neurobiology of Disease.
[45] Tomas Björklund,et al. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. , 2007, Current gene therapy.
[46] D. Tsuji,et al. Metabolic correction in microglia derived from Sandhoff disease model mice , 2005, Journal of neurochemistry.
[47] I. Martins,et al. The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[48] Inder M Verma,et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model , 2005, Nature Neuroscience.
[49] Kathleen A. Marshall,et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[50] William Jagust,et al. Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.
[51] S. Kasparov,et al. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] J. Mallet,et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Ballabio,et al. Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. , 2007, Human gene therapy.
[54] Nick Tyler,et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[55] M. Hayden,et al. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice , 2004, Experimental Neurology.
[56] Maria Jansson,et al. Targeted transgene expression in rat brain using lentiviral vectors , 2003, Journal of neuroscience research.
[57] Stanley J. Wiegand,et al. Neurotrophic factors: from molecule to man , 1994, Trends in Neurosciences.
[58] P. Aebischer,et al. Long‐term glial cell line‐derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production , 2005, Journal of neurochemistry.
[59] A. Kingsman,et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. , 2001, Human molecular genetics.
[60] Y. Arsenijévic,et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. , 2000, Human gene therapy.
[61] A. Björklund,et al. Localized striatal delivery of GDNF as a treatment for Parkinson disease , 2004, Nature Neuroscience.
[62] N. Mazarakis,et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[63] B. Strooper,et al. Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein , 2003, Brain pathology.
[64] H. Heinsen,et al. Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.
[65] S. Suhr,et al. Intraneuronal Aggregate Formation and Cell Death after Viral Expression of Expanded Polyglutamine Tracts in the Adult Rat Brain , 2000, The Journal of Neuroscience.
[66] C. Cain,et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. , 1997, Cell transplantation.
[67] H. Federoff,et al. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. , 2005, Brain research. Molecular brain research.
[68] N. Déglon,et al. Viral vectors as tools to model and treat neurodegenerative disorders , 2005, The journal of gene medicine.
[69] R. Moats,et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[70] S Shimohama,et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[71] J. Bloch,et al. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[72] H. Mizukami,et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease , 2002, Gene Therapy.
[73] A. Björklund,et al. In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated rat striatum , 1990, Neuron.
[74] S. Wachtel,et al. Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis ofl-DOPA by Primary Fibroblasts , 1996, The Journal of Neuroscience.
[75] A. Björklund,et al. Overexpression of Glial Cell Line-Derived Neurotrophic Factor Using a Lentiviral Vector Induces Time- and Dose-Dependent Downregulation of Tyrosine Hydroxylase in the Intact Nigrostriatal Dopamine System , 2004, The Journal of Neuroscience.
[76] Ronald L Klein,et al. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.
[77] L. Naldini,et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. , 2006, The Journal of clinical investigation.
[78] D. Kirik,et al. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft’s ability to improve spontaneous motor behavior in parkinsonian rats , 2006, Neuroscience.
[79] R. Levine,et al. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. , 1979, Science.
[80] B. Davidson,et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat , 1999, Gene Therapy.
[81] K. G. Rajeev,et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.
[82] J. Feldon,et al. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. , 2002, Journal of neurobiology.
[83] A. Björklund,et al. Aberrant Sprouting and Downregulation of Tyrosine Hydroxylase in Lesioned Nigrostriatal Dopamine Neurons Induced by Long-Lasting Overexpression of Glial Cell Line Derived Neurotrophic Factor in the Striatum by Lentiviral Gene Transfer , 2002, Experimental Neurology.
[84] N. Déglon,et al. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. , 2002, Human gene therapy.
[85] A. Bahi,et al. Silencing dopamine D3‐receptors in the nucleus accumbens shell in vivo induces changes in cocaine‐induced hyperlocomotion , 2005, The European journal of neuroscience.
[86] Christopher A. Ross,et al. Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.
[87] Emmanuel Brouillet,et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment , 2005, Neurobiology of Disease.
[88] D. Kirik,et al. Dissociation between short‐term increased graft survival and long‐term functional improvements in Parkinsonian rats overexpressing glial cell line‐derived neurotrophic factor , 2004, The European journal of neuroscience.
[89] E. Ranieri,et al. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. , 2008, Molecular genetics and metabolism.
[90] B. Pettmann,et al. Efficient Gene Transfer and Expression of Biologically Active Glial Cell Line‐Derived Neurotrophic Factor in Rat Motoneurons Transduced with Lentiviral Vectors , 2000 .
[91] M. Wyles,et al. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. , 2008, Current gene therapy.
[92] S. Dunnett,et al. Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model , 2005, The European journal of neuroscience.
[93] J. Qian,et al. Behavioral and Cellular Protection of Rat Dopaminergic Neurons by an Adenoviral Vector Encoding Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.
[94] J. Ridet,et al. Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF , 2000, Experimental Neurology.
[95] J. Nuyts,et al. Non-invasive imaging of neuropathology in a rat model of α-synuclein overexpression , 2007, Neurobiology of Aging.
[96] A. Björklund,et al. Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.
[97] A. Björklund,et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[98] N. Déglon,et al. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. , 2003, Human molecular genetics.
[99] L. Greensmith,et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model , 2005, Nature Medicine.
[100] J. Haycock,et al. l-Dopa and Dopamine-Producing Gene Cassettes for Gene Therapy Approaches to Parkinson's Disease , 1997, Experimental Neurology.
[101] S. Leff,et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[102] A. Pletscher,et al. In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin , 1974, Nature.
[103] D. Kirik,et al. Long‐term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system , 2003, The European journal of neuroscience.
[104] F. Gage,et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[105] N. Mazarakis,et al. Lentiviral vectors for treating and modeling human CNS disorders , 2004, The journal of gene medicine.
[106] O. Lindvall,et al. Neurotrophins and brain insults , 1994, Trends in Neurosciences.
[107] A. Poeppl,et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[108] F. Hefti,et al. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases , 1989, Neurobiology of Aging.
[109] F. Gage,et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[110] C. Lundberg,et al. Lentiviral vectors for use in the central nervous system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[111] E. Bongarzone,et al. Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[112] S. E. Barker,et al. Effective gene therapy with nonintegrating lentiviral vectors , 2006, Nature Medicine.
[113] A. West,et al. Tetrahydrobiopterin biosynthesis in C6 glioma cells: induction of GTP cyclohydrolase I gene expression by lipopolysaccharide and cytokine treatment. , 1996, Brain research. Molecular brain research.
[114] F. Gage,et al. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce l-dopa , 1991, Neuron.
[115] Fred H. Gage,et al. Neurogenesis in the Adult Brain , 2002, The Journal of Neuroscience.
[116] A. Kingsman,et al. Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease. , 2002, The Journal of Neuroscience.
[117] Mart Saarma,et al. The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.
[118] M. K. Sapru,et al. Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi , 2006, Experimental Neurology.
[119] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[120] S. Krajewski,et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II , 2008, Human molecular genetics.
[121] J. Kordower,et al. Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington’s Disease , 1996, The Journal of Neuroscience.
[122] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.